Skip to main
AGEN

Agenus (AGEN) Stock Forecast & Price Target

Agenus (AGEN) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Agenus Inc has a robust pipeline of therapies aimed at harnessing the immune system to combat cancer and infections, supported by in-house capabilities such as cGMP manufacturing. The company's compassionate use program for its antibody candidates, botensilimab and balstilimab, is anticipated to generate additional revenue and yield real-world clinical evidence for their applications, particularly in breast cancer treatments. Encouraging early regulatory sentiment for these therapies in various indications further enhances the company's growth potential and overall market outlook.

Bears say

Agenus Inc faces several significant risks that contribute to a negative outlook on its stock. Key concerns include the potential for emerging safety signals in its clinical and preclinical programs, which could undermine investor confidence and impact trials. Furthermore, the company may encounter challenges related to efficacy, competition in the market, regulatory hurdles, financing needs, and intellectual property protection, all of which add to uncertainty regarding its product pipeline and overall financial stability.

Agenus (AGEN) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Agenus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Agenus (AGEN) Forecast

Analysts have given Agenus (AGEN) a Buy based on their latest research and market trends.

According to 2 analysts, Agenus (AGEN) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Agenus (AGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.